The biosynthesis of testosterone relies on several steroidogenic enzymes, including cholesterol side-chain cleavage enzyme (CYP11A1), cytochrome P450 17α-hydroxylase/20-lyase (CYP17A1), 3β ...

Laekna announced that the FDA approved the Phase III clinical trial protocol for LAE002 (afuresertib, an AKT inhibitor) combined with LAE001 (a CYP17A1/CYP11B2 dual inhibitor) for the treatment of ...

The FDA has approved the phase 3 trial protocol of afuresertib plus LAE001, a CYP17A1/CYP11B2 dual inhibitor (LAE201) for the treatment of patients with mCRPC who have received standard-of-care (SOC) ...

LAE001 is an androgen synthesis inhibitor that inhibits both CYP17A1 and CYP11B2. Laekna in-licensed LAE001 from Novartis in 2017. According to Frost & Sullivan, LAE001 is the only dual ...

† Department of Biochemistry, University of Illinois at Urbana-Champaign, 505 South Goodwin Avenue, Urbana, Illinois 61801, United States ‡ Department of Chemistry, Marquette University, Milwaukee, ...

ABSTRACT: We retrospectively reviewed the outcome of docetaxel, EMP, and carboplatin (DEC) as second-line chemotherapy in castration-resistant prostate cancer (CRPC) patients previously treated with ...

Model validation for repurposing predicted the non-passage for most antihypertensive drugs and passage for CYP17A1 cancer drugs.

Of these men, one exhibited two cortisol-producing adenomas and had positive staining for CYP17A1 in both tumors. The other man’s adrenal had demonstrated one cortisol-producing adenoma and one ...

There was a significant decrease in gene expression of the hormone receptors AR, ERa, and LHR, and the steroidogenic enzymes StAR, 3bHSD, 17bHSD, and CYP17a1 in the testes of LHTN and SSHTN mice.

We focused on cytochrome P450 17α-hydroxylase (CYP17A1) which catalyses the production of dehydroepiandrosterone (DHEA), in the androgen biosynthesis pathway to elucidate effects on sex steroids in ...